Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zynlonta (Loncastuximab Tesirine-lpyl),ZynlontaStudy001,2022,USA,MDV,350,68,45,55,27.5,62,78,5,15,30,40,15,40,30,20,10,20,35,45,18,8,4,10,6,25,60,40,R-CHOP,DA-EPOCH-R,R-CVP,R-Bendamustine,0,0,0,30,70,55,15,45,40,65,2
Zynlonta (Loncastuximab Tesirine-lpyl),ZynlontaStudy002,2023,Germany,Claim Database,420,72,52,48,26.8,58,75,7,12,28,45,15,35,32,23,10,18,32,50,20,10,5,12,7,28,65,45,R-CHOP,DA-EPOCH-R,R-CVP,R-Bendamustine,0,0,0,35,75,60,10,50,40,70,3
Zynlonta (Loncastuximab Tesirine-lpyl),ZynlontaStudy003,2023,Japan,MDV,280,70,48,52,25.5,45,82,3,18,32,35,15,45,28,17,10,22,38,40,15,7,3,9,5,22,55,35,R-CHOP,DA-EPOCH-R,R-CVP,R-Bendamustine,0,0,0,25,65,50,20,40,40,60,2.5
